Abstract
Background: AMP-activated protein kinase (AMPK) is a protein kinase that maintains homeostasis in cells and organs. As a master regulator of metabolism, AMPK coordinates many metabolic reactions. AMPK is a key factor in diabetes and metabolic syndrome associated with dysregulation of the metabolic status. Recently, AMPK has also attracted attention as a tumor suppressor. The aim of this article is to discuss about the role of AMPK in diabetes as well as cancer and to evaluate its effectiveness in treatment and prevention of these diseases.
Method: We reviewed studies of signaling mechanism involving AMPK and research on the role of AMPK in human disease including diabetes and cancer. In particular, we focused our attention on clinical trials about cancer treatment and prevention targeting AMPK.
Results: Many experimental studies reported the relation of AMPK and various metabolic reactions, mainly regulating energy homeostasis. Recent studies showed effect of AMPK on arrest of cell cycle as well as suppression of inflammation, which are important factors for carcinogenesis. Although some clinical studies investigated cancer treatment and prevention targeting AMPK, the effective yields in clinical trial have been limited.
Conclusion: AMPK activation as represented by metformin showed to improve disorders associated with diabetes and metabolic syndrome and became a well-established treatment strategy for these diseases. The increasing evidence suggests that AMPK is a promising target in the treatment and prevention of cancer. Further investigation including long-term clinical trials with large sample size is needed.
Keywords: AMPK, diabetes, metabolic syndrome, cancer, chemoprevention, metformin, biguanide.
Current Pharmaceutical Design
Title:AMPK: Therapeutic Target for Diabetes and Cancer Prevention
Volume: 23 Issue: 25
Author(s): Shotaro Umezawa *, Takuma Higurashi and Atsushi Nakajima
Affiliation:
- Department of Gastroenteroloy and Hepatology, Yokohama City University School of Medicine, Yokohama,Japan
Keywords: AMPK, diabetes, metabolic syndrome, cancer, chemoprevention, metformin, biguanide.
Abstract: Background: AMP-activated protein kinase (AMPK) is a protein kinase that maintains homeostasis in cells and organs. As a master regulator of metabolism, AMPK coordinates many metabolic reactions. AMPK is a key factor in diabetes and metabolic syndrome associated with dysregulation of the metabolic status. Recently, AMPK has also attracted attention as a tumor suppressor. The aim of this article is to discuss about the role of AMPK in diabetes as well as cancer and to evaluate its effectiveness in treatment and prevention of these diseases.
Method: We reviewed studies of signaling mechanism involving AMPK and research on the role of AMPK in human disease including diabetes and cancer. In particular, we focused our attention on clinical trials about cancer treatment and prevention targeting AMPK.
Results: Many experimental studies reported the relation of AMPK and various metabolic reactions, mainly regulating energy homeostasis. Recent studies showed effect of AMPK on arrest of cell cycle as well as suppression of inflammation, which are important factors for carcinogenesis. Although some clinical studies investigated cancer treatment and prevention targeting AMPK, the effective yields in clinical trial have been limited.
Conclusion: AMPK activation as represented by metformin showed to improve disorders associated with diabetes and metabolic syndrome and became a well-established treatment strategy for these diseases. The increasing evidence suggests that AMPK is a promising target in the treatment and prevention of cancer. Further investigation including long-term clinical trials with large sample size is needed.
Export Options
About this article
Cite this article as:
Umezawa Shotaro *, Higurashi Takuma and Nakajima Atsushi , AMPK: Therapeutic Target for Diabetes and Cancer Prevention, Current Pharmaceutical Design 2017; 23 (25) . https://dx.doi.org/10.2174/0929867324666170713150440
DOI https://dx.doi.org/10.2174/0929867324666170713150440 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AZT: An Old Drug with New Perspectives
Current Clinical Pharmacology A Review on Anti-urease Potential of Coumarins
Current Drug Targets In vitro and in vivo Evaluation of Antitumor Drug-Loaded Aptamer Targeted Single-Walled Carbon Nanotubes System
Current Pharmaceutical Biotechnology Clostridium Difficile Infection Following Chemotherapy
Recent Patents on Anti-Infective Drug Discovery Recapitulation of Cancer Nanotherapeutics
Current Nanomedicine The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology The Role of Dietary Polyphenols in the Management of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology Preparation and Evaluation of in vitro Self-assembling HSA Nanoparticles for Cabazitaxel
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Design, In Silico Modelling, and Functionality Theory of Novel Folate Receptor Targeted Rutin Encapsulated Folic Acid Conjugated Keratin Nanoparticles for Effective Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Editorial [Peptides and Proteins in Cancer Therapy]
Protein & Peptide Letters Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Cells with Minimal Expression of the JAK/STAT Pathway Related Proteins STAT5a and the Prolactin Receptor: Evidence of an Alternate Prolactin Receptor Isoform in Breast Disease
Protein & Peptide Letters Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry